How Much Does Tirzepatide Cost? (2026)

Tirzepatide is the most effective single-agent pharmacotherapy for weight loss currently on the market — and at retail, one of the most expensive. The same active molecule is sold under two brand names at different price points for different FDA-approved uses, accessed through a manufacturer's direct program that substantially undercuts retail, and also available as a compounded product at roughly one-ninth of the brand-name list price. Navigating what you'll actually pay requires knowing which version is prescribed, who's paying, and how the regulatory landscape changed in late 2024 and 2025.

This guide covers every price path for tirzepatide in 2026 — brand-name retail, LillyDirect self-pay, commercial insurance, Medicare, and compounded — including what the legal status of compounding is now that the FDA has declared the shortage resolved, and the hidden costs that the advertised monthly figure typically leaves out.

Tirzepatide: two brand names, two approved uses, two price points

Tirzepatide is a dual GIP and GLP-1 receptor agonist — a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor simultaneously. This dual mechanism distinguishes it from semaglutide, which activates only the GLP-1 receptor, and is hypothesized to account for the larger average weight loss tirzepatide produces in trials. It is sold under two FDA-approved brand names by Eli Lilly:

• Mounjaro — FDA-approved for type 2 diabetes management. Weekly subcutaneous injection, doses from 2.5 mg titrating up to 15 mg. Retail list price: approximately $1,112 per month (28-day supply).
• Zepbound — FDA-approved for chronic weight management and obstructive sleep apnea in adults with obesity. Same weekly injection, same dose range. Retail list price: approximately $1,086 per month. Also available at substantially lower self-pay prices through Lilly's direct program.

As with semaglutide's Ozempic-versus-Wegovy pricing split, the price difference between Mounjaro and Zepbound reflects different approved indications and different formulary placement by insurers — not a difference in the tirzepatide molecule itself. A critical practical difference is that Lilly offers a self-pay pricing program (LillyDirect) for Zepbound but not for Mounjaro, which has significant implications for uninsured patients.

Tirzepatide price comparison: every access path in 2026

Access path	Monthly cost	Prescription required	Insurance applies	Notes
Brand Zepbound — retail list price	~$1,086	Yes	If covered	Most plans require prior auth; obesity coverage varies by employer
Brand Mounjaro — retail list price	~$1,112	Yes	If covered (T2D diagnosis)	More consistently covered than Zepbound; no self-pay direct program
LillyDirect — Zepbound self-pay starter doses	$299	Yes	No (self-pay only)	2.5 mg and 5 mg doses only; program pricing ends Dec 31, 2026
LillyDirect — Zepbound self-pay higher doses	$449	Yes	No (self-pay only)	7.5 mg and above; miss the 45-day refill window and Lilly bills full retail
Commercial insurance + Lilly savings card (Zepbound or Mounjaro covered)	~$25	Yes	Yes (required)	Card caps savings at $150/month, $1,950/year; 13-fill limit; expires Dec 31, 2026
Commercial insurance, plan does not cover Mounjaro	~$499	Yes	Yes (required for card)	Savings card "not covered" tier; only available to commercially insured patients
Medicare Part D — GLP-1 Bridge Program (Zepbound KwikPen)	$50	Yes	Yes (Part D)	Bridge launched July 1, 2026; KwikPen only; prior auth required; Mounjaro not included
Medicare Part D — Mounjaro (type 2 diabetes)	Varies	Yes	Yes (Part D)	Prior auth required; 2026 annual OOP cap $2,100 across all Part D drugs
Compounded tirzepatide — telehealth (patient-specific, 503A)	$119–$299	Yes	No	Shortage ended Dec 2024; only patient-specific prescriptions permitted; median $225

The brand-name pricing tiers explained

Retail list price: what you'd pay at a chain pharmacy without any program

Zepbound's approximately $1,086 monthly retail price and Mounjaro's $1,112 are what patients pay at a retail pharmacy with no insurance, no manufacturer savings program, and no GoodRx coupon. Unlike generic drugs, where discount programs create large price reductions, tirzepatide has no generic competitor. Eli Lilly's patents on Zepbound and Mounjaro run well into the 2030s, so there is no biosimilar or generic exerting downward pricing pressure. The retail list price is the practical ceiling, and for most patients the starting point for searching alternatives — not the price they will actually pay.³

LillyDirect: the $299 direct self-pay vial program

In 2023, Eli Lilly launched LillyDirect, a direct-to-consumer cash program that ships Zepbound single-dose vials directly to patients' homes. The self-pay pricing available through LillyDirect — $299 for the 2.5 mg and 5 mg starting doses, rising to $449 at 7.5 mg and above — is substantially below the $1,086 retail list price because Lilly bypasses the standard pharmacy distribution chain.

Several practical details about LillyDirect matter before relying on it as a long-term pricing assumption:

• Vials, not pens. LillyDirect ships single-dose vials rather than the pre-filled KwikPen used in retail pharmacies and covered under Medicare's Bridge Program. Drawing up a vial requires a syringe and is an additional step compared to the auto-injector pen.
• Dose escalation changes the price. The $299 starting price is for the two lowest doses. As a patient titrates upward toward a maintenance dose — the typical course over several months — the price rises to $449 per month. Anyone budgeting based on the $299 floor should understand that the floor applies only during dose titration.
• The 45-day refill rule. LillyDirect holds its program pricing only if refills are placed within 45 days of the prior shipment. Missing that window — due to travel, a gap in a prescription, or delayed decision — results in Lilly billing its standard retail price instead of the program price.
• Program pricing ends December 31, 2026. Lilly has set a sunset date for the current LillyDirect pricing tier. Patients who begin the program in late 2026 should confirm what happens to pricing at renewal before committing to a dose-titration schedule that extends into 2027.
• No Mounjaro self-pay equivalent. LillyDirect offers no self-pay pricing path for Mounjaro. An uninsured patient who is prescribed tirzepatide for type 2 diabetes cannot access LillyDirect pricing for that indication. Some prescribers may be able to prescribe Zepbound for appropriate patients with both weight management and diabetes concerns, but that is a clinical decision for the prescriber, not a pricing workaround to apply without medical guidance.
• Medicare and Medicaid excluded. Federal anti-kickback statute bars government-insurance beneficiaries from manufacturer direct-sale programs. Medicare and Medicaid patients cannot use LillyDirect pricing.

Commercial insurance and the Lilly savings card

Patients with commercial insurance plans that cover Zepbound or Mounjaro can activate a Lilly savings card to reduce their copay to approximately $25 per month. The terms as of September 2026 cap the card's savings at $150 per fill, $1,950 per year across 13 fills, and the card expires December 31, 2026.

Coverage itself is the harder variable. Commercial plans that cover Mounjaro for a documented type 2 diabetes diagnosis are more straightforward to navigate than plans covering Zepbound for weight management. Obesity coverage restrictions are more common than diabetes coverage restrictions; a growing number of employer plans have explicitly excluded GLP-1 weight-loss drugs from their formularies to control costs. Some large insurers, including certain BCBS plans, dropped Zepbound from standard commercial coverage in 2025, retaining it only on select FEP or enhanced benefit plans. Prior authorization is standard and typically requires BMI documentation, comorbidity documentation, and often evidence that the patient has attempted prior weight-loss interventions.

For Mounjaro when the plan does not cover it, the Lilly savings card has a separate "not covered" tier: eligible commercially insured patients can pay approximately $499 per month. This tier is only available to commercially insured patients — it is not available to uninsured patients paying entirely out of pocket, who remain dependent on LillyDirect or the compounded market.

Medicare: the Bridge Program and Part D coverage

Medicare Part D historically covered Mounjaro for type 2 diabetes but excluded GLP-1 drugs used solely for weight management. On July 1, 2026, the Medicare GLP-1 Bridge Program launched, making the Zepbound KwikPen available to eligible Part D enrollees at a $50 monthly copay for qualifying patients with obesity.⁴

Key distinctions for Medicare patients:

• The Bridge Program covers the Zepbound KwikPen, not the single-dose vials available through LillyDirect. Medicare beneficiaries who want Bridge pricing must be prescribed the KwikPen specifically.
• Mounjaro is not on the Bridge Program. Medicare Part D covers Mounjaro for type 2 diabetes through standard formulary access, with prior authorization required. The 2026 out-of-pocket cap of $2,100 across all Part D drugs applies; patients with other covered medications may reach $0 cost partway through the year.
• Manufacturer savings cards, including the Lilly savings card, are prohibited for Medicare patients by federal anti-kickback statute.
• The Bridge Program eligibility requires both Part D enrollment and prior authorization through the enrollee's specific plan. Approval is not automatic at enrollment.

Compounded tirzepatide: what it costs and what changed in 2024–2025

Compounded tirzepatide operated under unusually broad legal permission from 2022 through late 2024, when Zepbound and Mounjaro were on the FDA's official drug shortage list. That shortage status allowed licensed pharmacies to prepare tirzepatide for compounding — normally prohibited for essentially-copy versions of commercially available drugs — as a supply workaround. Telehealth providers partnered with compounding pharmacies to offer the same active molecule at $119 to $299 per month, as much as nine times cheaper than Zepbound's retail list price.

That broad legal permission ended when the FDA issued a declaratory order on December 19, 2024, determining that the national tirzepatide shortage was resolved.¹ The FDA had previously made and then revoked an October 2024 shortage-resolved determination following litigation from the Outsourcing Facilities Association; the December 2024 order reinstated the resolution determination after the FDA completed its reevaluation.

The FDA set staggered enforcement-discretion wind-down deadlines:

• 503A pharmacies (state-licensed compounders): enforcement discretion ended February 18, 2025.
• 503B outsourcing facilities (FDA-registered, federal CGMP standards): enforcement discretion ended March 19, 2025.

In 2026, compounded tirzepatide remains available under a narrower set of conditions than during the shortage period. Under current 503A rules, state-licensed pharmacies may still prepare patient-specific tirzepatide prescriptions when a licensed physician documents a clinical need the brand product cannot address — for example, a required concentration or formulation not available in Zepbound or Mounjaro. Mass-produced compounded tirzepatide that is essentially a copy of the approved drug is no longer permitted.

Despite the narrower legal lane, many telehealth platforms have remained active by documenting patient-specific clinical justifications. As of September 2026, compounded tirzepatide prices range from $119 to $299 per month, with a median of approximately $225 per month across 42 tracked providers in the GLP-1 Watchdog Price Index. The lowest verified prices in that index are $119 per month from a handful of providers, though pricing varies by dose and program structure.

FDA safety concerns with compounded GLP-1 products

Before the tirzepatide shortage resolved, the FDA issued public alerts documenting safety concerns with compounded injectable GLP-1 products, including tirzepatide. The concerns are worth understanding before evaluating the price tradeoff.

The FDA has flagged that some compounders use salt forms of tirzepatide — such as tirzepatide acetate or tirzepatide trifluoroacetate — rather than the base form used in Zepbound and Mounjaro. The agency has stated it "is not aware of any basis" for these salt forms to meet the conditions required for compounding under 503A.¹ The safety and pharmacokinetic profiles of tirzepatide salt forms have not been established in clinical trials. Patients considering compounded tirzepatide should ask their provider explicitly whether the dispensing pharmacy uses the tirzepatide base or a salt form.

Dosing error risk is a second concern. Brand-name Zepbound and Mounjaro are dispensed in a KwikPen format with preset doses; LillyDirect vials come as single-dose vials. Compounded tirzepatide typically arrives as a multi-dose vial that the patient draws up with a syringe, requiring the patient to measure the correct volume — a less familiar task for most patients and one that has produced overdosing errors in the related semaglutide compounding market.

The clinical evidence that explains tirzepatide's premium pricing

Tirzepatide's retail price carries the embedded cost of the SURMOUNT clinical trial program, which produced the FDA approval data for weight management. The registration trial, SURMOUNT-1, enrolled 2,539 adults with obesity or overweight with comorbidities (without type 2 diabetes) and found that once-weekly tirzepatide produced mean weight loss of 15.0%, 19.5%, and 20.9% at the 5, 10, and 15 mg maintenance doses, respectively, over 72 weeks — compared to 3.1% with placebo.² More than half of participants on the highest dose achieved at least 20% body weight loss, a threshold previously associated primarily with bariatric surgery.

"Obesity and overweight are serious conditions that can be associated with some of the leading causes of death such as heart disease, stroke and diabetes." — Dr. John Sharretts, M.D., Director, Division of Diabetes, Lipid Disorders, and Obesity, FDA Center for Drug Evaluation and Research, at Zepbound's 2023 approval³

That efficacy data — specifically the roughly 6 percentage points of additional weight loss compared to semaglutide in indirect comparison — explains both why tirzepatide commands a premium over semaglutide at every price tier and why payers face pressure to cover it despite higher costs. Compounded tirzepatide makes the same claim to efficacy because the active pharmaceutical ingredient is the same; what it cannot claim is that the finished compounded product was manufactured under the same conditions, at the same validated doses, with the same quality testing as the brand-name drug.

Why tirzepatide costs more than semaglutide at every tier

The premium tirzepatide commands over semaglutide at every price point — compounded tirzepatide at $119–$299 versus compounded semaglutide at $69–$249 — reflects two structural differences in the active pharmaceutical ingredient itself, not just brand pricing decisions:

• Molecular complexity. Tirzepatide is a 39-amino-acid peptide with a C20 fatty diacid moiety attached. Its larger, more complex structure makes the raw active pharmaceutical ingredient more expensive to synthesize than semaglutide, which is a 31-amino-acid peptide.
• Therapeutic dose mass. Tirzepatide's therapeutic doses — in the milligram range at maintenance — are substantially higher by mass than semaglutide's sub-milligram therapeutic doses. Each vial of compounded tirzepatide requires more active ingredient per dose than a comparable semaglutide vial, which flows through directly to manufacturing cost.

The cost-per-percentage-point-of-weight-loss math is roughly comparable between the two drugs at current pricing. Patients who have been on semaglutide and reached a plateau, or who have a higher starting weight, may find the clinical and economic case for tirzepatide's premium compelling; for others, semaglutide remains a lower-cost starting point in the same drug class. For a full comparison of these two approaches, including the evidentiary differences and compounding considerations, our semaglutide cost guide covers the semaglutide side of the equation, and our general peptides for weight loss overview covers the broader category.

Hidden costs and the real total of a supervised tirzepatide program

Advertised monthly prices frequently represent only part of what a patient will actually spend. A realistic accounting across the three main cash pathways:

Brand-name pathway (with commercial insurance)

• Prior authorization: No direct cost to the patient, but the documentation process typically takes 1–6 weeks, requires physician time and comorbidity records, and is frequently denied on first submission for obesity indications. Factor in the time and administrative friction, not just the copay.
• Copay after approval: ~$25 per month with the Lilly savings card for covered patients; $50 per month for eligible Medicare enrollees under the Bridge Program.
• Physician visits and follow-up: Initial evaluation and periodic monitoring visits; telehealth visits through GLP-1 platforms typically run $75–$150 each. Labs (HbA1c, metabolic panel) add periodic costs depending on the prescriber's protocol.

LillyDirect self-pay pathway

• Prescription visit: $0–$150 for a telehealth evaluation if LillyDirect's partner telehealth is used; more if seen by an outside provider.
• Monthly medication cost: $299 at starting doses; $449 at maintenance doses of 7.5 mg and above.
• Supplies: Single-dose vials ship with or without a syringe depending on the format; bacteriostatic water is not required for the LillyDirect vials (they are ready-to-use). Sharps disposal containers add a small ongoing cost.
• Realistic annual total: $3,600–$5,500 depending on what maintenance dose is reached and how quickly titration progresses.

Compounded telehealth pathway

• Consultation fee: $0–$150 depending on the platform; many bundle it into the subscription.
• Monthly medication cost: $119–$299 at advertised rates. Ask specifically about dose-escalation pricing — many platforms advertise a low starting price that increases at maintenance doses.
• Injection supplies: Multi-dose vials require syringes, alcohol swabs, and bacteriostatic water where applicable; budget $15–$30 per month for supplies in addition to the medication cost.
• Realistic annual total: $1,600–$4,000 depending on dose, provider, and consultation model.

Questions to ask before committing to any tirzepatide program

• Which pharmacy dispenses the compounded version, and is it licensed? For compounded tirzepatide, the dispensing pharmacy should be either an FDA-registered 503B outsourcing facility (verifiable on the FDA website) or a state-licensed 503A pharmacy (verifiable through the relevant state pharmacy board). Ask for the pharmacy's name and license number before enrolling.
• Does your provider use tirzepatide base or a salt form? Tirzepatide acetate, trifluoroacetate, and other salt forms are different substances from the base form used in the approved drug. The FDA has raised concerns about salt-form compounding. Ask explicitly before your first dose.
• What is the full dose-escalation price schedule? The advertised entry price often applies only at the starting dose. Get the price at every titration step before committing to the program.
• What happens to LillyDirect pricing on January 1, 2027? If you are planning around LillyDirect pricing and expect to still need the medication in 2027, confirm with Lilly or your provider what the updated pricing structure will be before building a long-term budget around the current rates.
• What is included in the monthly fee? Some platforms bundle consultations, follow-up messaging, labs, and supplies; others bill each separately. Get an itemized breakdown before you pay.
• Is your prescriber documenting a patient-specific clinical justification for the compounded version? Post-shortage 503A rules require this documentation. Without it, the prescription may not be legally dispensable, and a pharmacy that does not require it may be operating outside current enforcement policy.

What this page cannot tell you

This guide covers pricing. It cannot tell you whether tirzepatide is clinically appropriate for your situation, what dose is right, whether the benefit outweighs the risks for your specific health history, or whether a physician reviewing your records would prescribe it. Those questions require a licensed physician who has seen your medical history. The regulatory status of compounded tirzepatide has changed repeatedly since 2022 and may change again; verify the current enforcement posture with your prescriber and pharmacy at the time you fill — not based on any guide including this one.

For comparison with semaglutide pricing across all GLP-1 class drugs, our semaglutide cost guide covers the Ozempic, Wegovy, and Rybelsus side of the equation. For the broader category of prescription versus research-grade peptides and the full risk/cost tradeoff of the telehealth channel, telehealth versus research vendors covers that comparison. For foundational context on what tirzepatide is as a peptide drug and where it sits relative to unapproved research peptides, that guide covers the categorical distinctions.